RU2553676C2 - СПОСОБ ПОЛУЧЕНИЯ ПРОИЗВОДНОГО БЕНЗО[b][1,4]ДИАЗЕПИН-2,4-ДИОНА - Google Patents
СПОСОБ ПОЛУЧЕНИЯ ПРОИЗВОДНОГО БЕНЗО[b][1,4]ДИАЗЕПИН-2,4-ДИОНА Download PDFInfo
- Publication number
- RU2553676C2 RU2553676C2 RU2012110566/04A RU2012110566A RU2553676C2 RU 2553676 C2 RU2553676 C2 RU 2553676C2 RU 2012110566/04 A RU2012110566/04 A RU 2012110566/04A RU 2012110566 A RU2012110566 A RU 2012110566A RU 2553676 C2 RU2553676 C2 RU 2553676C2
- Authority
- RU
- Russia
- Prior art keywords
- formula
- compound represented
- group
- compound
- reaction
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 43
- LPEPHAJSOWLSAF-UHFFFAOYSA-N 1,5-benzodiazepine-2,4-dione Chemical class O=C1CC(=O)N=C2C=CC=CC2=N1 LPEPHAJSOWLSAF-UHFFFAOYSA-N 0.000 title description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 204
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 26
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims abstract description 16
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 15
- 125000006239 protecting group Chemical group 0.000 claims abstract description 14
- 239000003638 chemical reducing agent Substances 0.000 claims abstract description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 10
- 230000009467 reduction Effects 0.000 claims abstract description 5
- 230000003993 interaction Effects 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 12
- 125000005843 halogen group Chemical group 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 125000002252 acyl group Chemical group 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 230000003288 anthiarrhythmic effect Effects 0.000 abstract 1
- 239000013067 intermediate product Substances 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 112
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 102
- 239000000203 mixture Substances 0.000 description 77
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 76
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 75
- 239000000243 solution Substances 0.000 description 66
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 54
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 51
- 239000013078 crystal Substances 0.000 description 47
- 239000002904 solvent Substances 0.000 description 42
- 230000015572 biosynthetic process Effects 0.000 description 40
- 238000003786 synthesis reaction Methods 0.000 description 38
- 238000005160 1H NMR spectroscopy Methods 0.000 description 37
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- 238000001816 cooling Methods 0.000 description 32
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 29
- 238000001914 filtration Methods 0.000 description 27
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 24
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 24
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 22
- -1 methoxy, ethoxy, propoxy, isopropoxy Chemical group 0.000 description 20
- 239000000047 product Substances 0.000 description 19
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 18
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- 239000002168 alkylating agent Substances 0.000 description 15
- 229940100198 alkylating agent Drugs 0.000 description 15
- 150000007514 bases Chemical class 0.000 description 15
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 13
- 150000001298 alcohols Chemical class 0.000 description 13
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 12
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 12
- 239000008096 xylene Substances 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 11
- 239000012044 organic layer Substances 0.000 description 11
- 229910000027 potassium carbonate Inorganic materials 0.000 description 11
- 235000011181 potassium carbonates Nutrition 0.000 description 11
- 239000003054 catalyst Substances 0.000 description 10
- 238000010992 reflux Methods 0.000 description 10
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 8
- 235000019445 benzyl alcohol Nutrition 0.000 description 8
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 8
- 150000002170 ethers Chemical class 0.000 description 8
- AECXJADMKJXBOY-UHFFFAOYSA-N n-methyl-2-nitro-5-phenylmethoxyaniline Chemical compound C1=C([N+]([O-])=O)C(NC)=CC(OCC=2C=CC=CC=2)=C1 AECXJADMKJXBOY-UHFFFAOYSA-N 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 7
- 229910052783 alkali metal Inorganic materials 0.000 description 7
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 7
- 239000003444 phase transfer catalyst Substances 0.000 description 7
- 239000002798 polar solvent Substances 0.000 description 7
- 239000012312 sodium hydride Substances 0.000 description 7
- 229910000104 sodium hydride Inorganic materials 0.000 description 7
- RJXOVESYJFXCGI-UHFFFAOYSA-N 2,4-difluoro-1-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1F RJXOVESYJFXCGI-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
- 108091006146 Channels Proteins 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 5
- DSVGQVZAZSZEEX-UHFFFAOYSA-N [C].[Pt] Chemical compound [C].[Pt] DSVGQVZAZSZEEX-UHFFFAOYSA-N 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 206010003119 arrhythmia Diseases 0.000 description 5
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 5
- 150000007529 inorganic bases Chemical class 0.000 description 5
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 5
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 5
- 150000007530 organic bases Chemical class 0.000 description 5
- 150000004714 phosphonium salts Chemical class 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 5
- 238000006722 reduction reaction Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 4
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 4
- SGUVLZREKBPKCE-UHFFFAOYSA-N 1,5-diazabicyclo[4.3.0]-non-5-ene Chemical compound C1CCN=C2CCCN21 SGUVLZREKBPKCE-UHFFFAOYSA-N 0.000 description 4
- PQMDCEKVIAETHO-UHFFFAOYSA-N 1-ethyl-3,3,5-trimethyl-7-phenylmethoxy-1,5-benzodiazepine-2,4-dione Chemical compound C1=C2N(C)C(=O)C(C)(C)C(=O)N(CC)C2=CC=C1OCC1=CC=CC=C1 PQMDCEKVIAETHO-UHFFFAOYSA-N 0.000 description 4
- HDQNXIOVYVAKBX-UHFFFAOYSA-N 5-fluoro-n-methyl-2-nitroaniline Chemical compound CNC1=CC(F)=CC=C1[N+]([O-])=O HDQNXIOVYVAKBX-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 150000008282 halocarbons Chemical class 0.000 description 4
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 4
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 4
- 125000006702 (C1-C18) alkyl group Chemical group 0.000 description 3
- VDCQWQFQERIQCO-UHFFFAOYSA-N 1-ethyl-5-methyl-7-phenylmethoxy-1,5-benzodiazepine-2,4-dione Chemical compound C1=C2N(C)C(=O)CC(=O)N(CC)C2=CC=C1OCC1=CC=CC=C1 VDCQWQFQERIQCO-UHFFFAOYSA-N 0.000 description 3
- MFGOFGRYDNHJTA-UHFFFAOYSA-N 2-amino-1-(2-fluorophenyl)ethanol Chemical compound NCC(O)C1=CC=CC=C1F MFGOFGRYDNHJTA-UHFFFAOYSA-N 0.000 description 3
- GFAQAEVMRCIWEB-UHFFFAOYSA-N 3,3,5-trimethyl-7-phenylmethoxy-1h-1,5-benzodiazepine-2,4-dione Chemical compound C=1C=C2NC(=O)C(C)(C)C(=O)N(C)C2=CC=1OCC1=CC=CC=C1 GFAQAEVMRCIWEB-UHFFFAOYSA-N 0.000 description 3
- AXNUJYHFQHQZBE-UHFFFAOYSA-N 3-methylbenzene-1,2-diamine Chemical compound CC1=CC=CC(N)=C1N AXNUJYHFQHQZBE-UHFFFAOYSA-N 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- 101000944266 Homo sapiens G protein-activated inward rectifier potassium channel 1 Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 3
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 3
- 150000008041 alkali metal carbonates Chemical class 0.000 description 3
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 3
- 150000001340 alkali metals Chemical class 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- 230000001746 atrial effect Effects 0.000 description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 description 3
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Inorganic materials [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- LTYMSROWYAPPGB-UHFFFAOYSA-N diphenyl sulfide Chemical compound C=1C=CC=CC=1SC1=CC=CC=C1 LTYMSROWYAPPGB-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 210000002837 heart atrium Anatomy 0.000 description 3
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 3
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 3
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 3
- 229910052808 lithium carbonate Inorganic materials 0.000 description 3
- 229910000032 lithium hydrogen carbonate Inorganic materials 0.000 description 3
- HQRPHMAXFVUBJX-UHFFFAOYSA-M lithium;hydrogen carbonate Chemical compound [Li+].OC([O-])=O HQRPHMAXFVUBJX-UHFFFAOYSA-M 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 3
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 3
- 235000015497 potassium bicarbonate Nutrition 0.000 description 3
- 239000011736 potassium bicarbonate Substances 0.000 description 3
- RPDAUEIUDPHABB-UHFFFAOYSA-N potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 description 3
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 3
- 229910000105 potassium hydride Inorganic materials 0.000 description 3
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 3
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- BDAWXSQJJCIFIK-UHFFFAOYSA-N potassium methoxide Chemical compound [K+].[O-]C BDAWXSQJJCIFIK-UHFFFAOYSA-N 0.000 description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
- UMHSKYSHOIGDPE-UHFFFAOYSA-N pyridine;quinoline Chemical compound C1=CC=NC=C1.N1=CC=CC2=CC=CC=C21 UMHSKYSHOIGDPE-UHFFFAOYSA-N 0.000 description 3
- 230000036279 refractory period Effects 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 231100000167 toxic agent Toxicity 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 3
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 3
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 2
- ZSOLVCDNANFVCX-UHFFFAOYSA-N 1,3,3-trimethyl-6-phenylmethoxy-5h-1,5-benzodiazepine-2,4-dione Chemical compound C=12NC(=O)C(C)(C)C(=O)N(C)C2=CC=CC=1OCC1=CC=CC=C1 ZSOLVCDNANFVCX-UHFFFAOYSA-N 0.000 description 2
- SSNCMIDZGFCTST-UHFFFAOYSA-N 1,3-difluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=C(F)C=CC=C1F SSNCMIDZGFCTST-UHFFFAOYSA-N 0.000 description 2
- XNUYIFKYTHNGIH-UHFFFAOYSA-N 1-ethyl-3,5-dimethyl-7-phenylmethoxy-1,5-benzodiazepine-2,4-dione Chemical compound C1=C2N(C)C(=O)C(C)C(=O)N(CC)C2=CC=C1OCC1=CC=CC=C1 XNUYIFKYTHNGIH-UHFFFAOYSA-N 0.000 description 2
- ZHBMOURQWKNAOL-UHFFFAOYSA-N 1-ethyl-7-hydroxy-3,3,5-trimethyl-1,5-benzodiazepine-2,4-dione Chemical compound CN1C(=O)C(C)(C)C(=O)N(CC)C2=CC=C(O)C=C21 ZHBMOURQWKNAOL-UHFFFAOYSA-N 0.000 description 2
- CJXQAYQWVNXIQE-UHFFFAOYSA-N 2,2-dimethylpropanedioyl dichloride Chemical compound ClC(=O)C(C)(C)C(Cl)=O CJXQAYQWVNXIQE-UHFFFAOYSA-N 0.000 description 2
- KDSNLYIMUZNERS-UHFFFAOYSA-N 2-methylpropanamine Chemical compound CC(C)CN KDSNLYIMUZNERS-UHFFFAOYSA-N 0.000 description 2
- JBYOOHVCUSDDCE-UHFFFAOYSA-N 3-fluoro-n-methyl-2-nitroaniline Chemical compound CNC1=CC=CC(F)=C1[N+]([O-])=O JBYOOHVCUSDDCE-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- PVJROUWJVWIGMK-UHFFFAOYSA-N 5-methyl-7-phenylmethoxy-1h-1,5-benzodiazepine-2,4-dione Chemical compound C=1C=C2NC(=O)CC(=O)N(C)C2=CC=1OCC1=CC=CC=C1 PVJROUWJVWIGMK-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 206010008088 Cerebral artery embolism Diseases 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 102100033063 G protein-activated inward rectifier potassium channel 1 Human genes 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000036982 action potential Effects 0.000 description 2
- 229910001516 alkali metal iodide Inorganic materials 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 239000003416 antiarrhythmic agent Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- JGDFBJMWFLXCLJ-UHFFFAOYSA-N copper chromite Chemical compound [Cu]=O.[Cu]=O.O=[Cr]O[Cr]=O JGDFBJMWFLXCLJ-UHFFFAOYSA-N 0.000 description 2
- 238000006264 debenzylation reaction Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 239000012156 elution solvent Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 201000010849 intracranial embolism Diseases 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 125000002346 iodo group Chemical group I* 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- MVLUKKOMVMRLNE-UHFFFAOYSA-N n-methyl-2-nitro-3-phenylmethoxyaniline Chemical compound CNC1=CC=CC(OCC=2C=CC=CC=2)=C1[N+]([O-])=O MVLUKKOMVMRLNE-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229910003446 platinum oxide Inorganic materials 0.000 description 2
- 229960003975 potassium Drugs 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- DWSGLSZEOZQMSP-UHFFFAOYSA-N potassium;sodium Chemical compound [Na+].[K+] DWSGLSZEOZQMSP-UHFFFAOYSA-N 0.000 description 2
- 230000001536 pro-arrhythmogenic effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- VDZOOKBUILJEDG-UHFFFAOYSA-M tetrabutylammonium hydroxide Chemical compound [OH-].CCCC[N+](CCCC)(CCCC)CCCC VDZOOKBUILJEDG-UHFFFAOYSA-M 0.000 description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 0 *c1ccccc1N Chemical compound *c1ccccc1N 0.000 description 1
- ORYCHCBYJBVZIM-UHFFFAOYSA-N 1,5-diethyl-3,3-dimethyl-7-phenylmethoxy-1,5-benzodiazepine-2,4-dione Chemical compound C1=C2N(CC)C(=O)C(C)(C)C(=O)N(CC)C2=CC=C1OCC1=CC=CC=C1 ORYCHCBYJBVZIM-UHFFFAOYSA-N 0.000 description 1
- BLPDLWZHFRELCN-UHFFFAOYSA-N 1,5-diethyl-7-hydroxy-3,3-dimethyl-1,5-benzodiazepine-2,4-dione Chemical compound CCN1C(=O)C(C)(C)C(=O)N(CC)C2=CC=C(O)C=C21 BLPDLWZHFRELCN-UHFFFAOYSA-N 0.000 description 1
- QQCZVNKTIRRRFB-UHFFFAOYSA-N 1-butyl-3,3,5-trimethyl-7-phenylmethoxy-1,5-benzodiazepine-2,4-dione Chemical compound C1=C2N(C)C(=O)C(C)(C)C(=O)N(CCCC)C2=CC=C1OCC1=CC=CC=C1 QQCZVNKTIRRRFB-UHFFFAOYSA-N 0.000 description 1
- YXCMZJJBJXPIBR-UHFFFAOYSA-N 1-butyl-7-hydroxy-3,3,5-trimethyl-1,5-benzodiazepine-2,4-dione Chemical compound CN1C(=O)C(C)(C)C(=O)N(CCCC)C2=CC=C(O)C=C21 YXCMZJJBJXPIBR-UHFFFAOYSA-N 0.000 description 1
- GKQHIYSTBXDYNQ-UHFFFAOYSA-M 1-dodecylpyridin-1-ium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+]1=CC=CC=C1 GKQHIYSTBXDYNQ-UHFFFAOYSA-M 0.000 description 1
- CUTHDNILLLLXRS-UHFFFAOYSA-N 1-ethyl-3,3-dimethyl-5-(2-methylpropyl)-7-phenylmethoxy-1,5-benzodiazepine-2,4-dione Chemical compound C1=C2N(CC(C)C)C(=O)C(C)(C)C(=O)N(CC)C2=CC=C1OCC1=CC=CC=C1 CUTHDNILLLLXRS-UHFFFAOYSA-N 0.000 description 1
- RZJNCGQKWOAFEB-UHFFFAOYSA-N 1-ethyl-7-hydroxy-3,3-dimethyl-5-(2-methylpropyl)-1,5-benzodiazepine-2,4-dione Chemical compound CC(C)CN1C(=O)C(C)(C)C(=O)N(CC)C2=CC=C(O)C=C21 RZJNCGQKWOAFEB-UHFFFAOYSA-N 0.000 description 1
- GCUDZXAXPLTOBD-UHFFFAOYSA-N 1-ethyl-7-hydroxy-5-methyl-1,5-benzodiazepine-2,4-dione Chemical compound CN1C(=O)CC(=O)N(CC)C2=CC=C(O)C=C21 GCUDZXAXPLTOBD-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- 125000006508 2,6-difluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C(F)=C1[H])C([H])([H])* 0.000 description 1
- IPOVOSHRRIJKBR-UHFFFAOYSA-N 2-ethylpropanedioyl dichloride Chemical compound CCC(C(Cl)=O)C(Cl)=O IPOVOSHRRIJKBR-UHFFFAOYSA-N 0.000 description 1
- FOVUGENWTAFTDY-UHFFFAOYSA-N 2-n-ethyl-4-phenylmethoxybenzene-1,2-diamine;hydrochloride Chemical compound Cl.C1=C(N)C(NCC)=CC(OCC=2C=CC=CC=2)=C1 FOVUGENWTAFTDY-UHFFFAOYSA-N 0.000 description 1
- SLLOXCPWBASPJK-UHFFFAOYSA-N 2-n-methyl-4-phenylmethoxybenzene-1,2-diamine;hydrochloride Chemical compound Cl.C1=C(N)C(NC)=CC(OCC=2C=CC=CC=2)=C1 SLLOXCPWBASPJK-UHFFFAOYSA-N 0.000 description 1
- RTCMHQBJPRKTNC-UHFFFAOYSA-N 3,3,5-trimethyl-1-(3-methylbutyl)-7-phenylmethoxy-1,5-benzodiazepine-2,4-dione Chemical compound C1=C2N(C)C(=O)C(C)(C)C(=O)N(CCC(C)C)C2=CC=C1OCC1=CC=CC=C1 RTCMHQBJPRKTNC-UHFFFAOYSA-N 0.000 description 1
- SQDLSHIAIMZXET-UHFFFAOYSA-N 3,3-diethyl-5-methyl-7-phenylmethoxy-1h-1,5-benzodiazepine-2,4-dione Chemical compound C1=C2N(C)C(=O)C(CC)(CC)C(=O)NC2=CC=C1OCC1=CC=CC=C1 SQDLSHIAIMZXET-UHFFFAOYSA-N 0.000 description 1
- VMPKOKGTWHTJIP-UHFFFAOYSA-N 3,3-diethyl-7-hydroxy-5-methyl-1h-1,5-benzodiazepine-2,4-dione Chemical compound CN1C(=O)C(CC)(CC)C(=O)NC2=CC=C(O)C=C21 VMPKOKGTWHTJIP-UHFFFAOYSA-N 0.000 description 1
- AMRAPQUBNJAADC-UHFFFAOYSA-N 3,3-dimethyl-5-(2-methylpropyl)-7-phenylmethoxy-1h-1,5-benzodiazepine-2,4-dione Chemical compound C=1C=C2NC(=O)C(C)(C)C(=O)N(CC(C)C)C2=CC=1OCC1=CC=CC=C1 AMRAPQUBNJAADC-UHFFFAOYSA-N 0.000 description 1
- WSYGAUYADSLNBI-UHFFFAOYSA-N 3-butyl-1-ethyl-3,5-dimethyl-7-phenylmethoxy-1,5-benzodiazepine-2,4-dione Chemical compound C=1C=C2N(CC)C(=O)C(CCCC)(C)C(=O)N(C)C2=CC=1OCC1=CC=CC=C1 WSYGAUYADSLNBI-UHFFFAOYSA-N 0.000 description 1
- MSVNEDXYERTMAW-UHFFFAOYSA-N 3-butyl-1-ethyl-7-hydroxy-3,5-dimethyl-1,5-benzodiazepine-2,4-dione Chemical compound CCN1C(=O)C(CCCC)(C)C(=O)N(C)C2=CC(O)=CC=C21 MSVNEDXYERTMAW-UHFFFAOYSA-N 0.000 description 1
- BICRSXAZUOUWNO-UHFFFAOYSA-N 5-ethyl-1,3,3-trimethyl-6-phenylmethoxy-1,5-benzodiazepine-2,4-dione Chemical compound C1=CC=C2N(C)C(=O)C(C)(C)C(=O)N(CC)C2=C1OCC1=CC=CC=C1 BICRSXAZUOUWNO-UHFFFAOYSA-N 0.000 description 1
- YGDOWQSBEXALQB-UHFFFAOYSA-N 5-ethyl-3,3-dimethyl-7-phenylmethoxy-1h-1,5-benzodiazepine-2,4-dione Chemical compound C=1C=C2NC(=O)C(C)(C)C(=O)N(CC)C2=CC=1OCC1=CC=CC=C1 YGDOWQSBEXALQB-UHFFFAOYSA-N 0.000 description 1
- QGPPTWHVEUCPLK-UHFFFAOYSA-N 5-ethyl-6-hydroxy-1,3,3-trimethyl-1,5-benzodiazepine-2,4-dione Chemical compound CN1C(=O)C(C)(C)C(=O)N(CC)C2=C(O)C=CC=C21 QGPPTWHVEUCPLK-UHFFFAOYSA-N 0.000 description 1
- WEELMLLGBKXGMT-UHFFFAOYSA-N 5-fluoro-n-(2-methylpropyl)-2-nitroaniline Chemical compound CC(C)CNC1=CC(F)=CC=C1[N+]([O-])=O WEELMLLGBKXGMT-UHFFFAOYSA-N 0.000 description 1
- FPWKNDJVBIJDIR-UHFFFAOYSA-N 7-hydroxy-3,3,5-trimethyl-1-(3-methylbutyl)-1,5-benzodiazepine-2,4-dione Chemical compound CN1C(=O)C(C)(C)C(=O)N(CCC(C)C)C2=CC=C(O)C=C21 FPWKNDJVBIJDIR-UHFFFAOYSA-N 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 208000002102 Atrial Premature Complexes Diseases 0.000 description 1
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical group N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102100021237 G protein-activated inward rectifier potassium channel 4 Human genes 0.000 description 1
- 101000614712 Homo sapiens G protein-activated inward rectifier potassium channel 4 Proteins 0.000 description 1
- 101001047090 Homo sapiens Potassium voltage-gated channel subfamily H member 2 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 description 1
- GEYBMYRBIABFTA-UHFFFAOYSA-N O-methyltyrosine Chemical compound COC1=CC=C(CC(N)C(O)=O)C=C1 GEYBMYRBIABFTA-UHFFFAOYSA-N 0.000 description 1
- 102100022807 Potassium voltage-gated channel subfamily H member 2 Human genes 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- VJGNLOIQCWLBJR-UHFFFAOYSA-M benzyl(tributyl)azanium;chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CC1=CC=CC=C1 VJGNLOIQCWLBJR-UHFFFAOYSA-M 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- KMGBZBJJOKUPIA-UHFFFAOYSA-N butyl iodide Chemical compound CCCCI KMGBZBJJOKUPIA-UHFFFAOYSA-N 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 125000004803 chlorobenzyl group Chemical group 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- BOTLEXFFFSMRLQ-UHFFFAOYSA-N cyclopentyloxycyclopentane Chemical compound C1CCCC1OC1CCCC1 BOTLEXFFFSMRLQ-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- DENRZWYUOJLTMF-UHFFFAOYSA-N diethyl sulfate Chemical compound CCOS(=O)(=O)OCC DENRZWYUOJLTMF-UHFFFAOYSA-N 0.000 description 1
- 229940008406 diethyl sulfate Drugs 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- IXTMWRCNAAVVAI-UHFFFAOYSA-N dofetilide Chemical compound C=1C=C(NS(C)(=O)=O)C=CC=1CCN(C)CCOC1=CC=C(NS(C)(=O)=O)C=C1 IXTMWRCNAAVVAI-UHFFFAOYSA-N 0.000 description 1
- 229960002994 dofetilide Drugs 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000004175 fluorobenzyl group Chemical group 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005935 hexyloxycarbonyl group Chemical group 0.000 description 1
- RKUPXQGCEBDURP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfite Chemical compound OS([O-])=O.CCCC[N+](CCCC)(CCCC)CCCC RKUPXQGCEBDURP-UHFFFAOYSA-M 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- VUQUOGPMUUJORT-UHFFFAOYSA-N methyl 4-methylbenzenesulfonate Chemical compound COS(=O)(=O)C1=CC=C(C)C=C1 VUQUOGPMUUJORT-UHFFFAOYSA-N 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- CSPUHTVEZIKIHH-UHFFFAOYSA-N n-(2-methylpropyl)-2-nitro-5-phenylmethoxyaniline Chemical compound C1=C([N+]([O-])=O)C(NCC(C)C)=CC(OCC=2C=CC=CC=2)=C1 CSPUHTVEZIKIHH-UHFFFAOYSA-N 0.000 description 1
- 125000006606 n-butoxy group Chemical group 0.000 description 1
- YMDUNSVJPHEFNS-UHFFFAOYSA-N n-ethyl-2-nitro-5-phenylmethoxyaniline Chemical compound C1=C([N+]([O-])=O)C(NCC)=CC(OCC=2C=CC=CC=2)=C1 YMDUNSVJPHEFNS-UHFFFAOYSA-N 0.000 description 1
- BBXLSURFRDKKLF-UHFFFAOYSA-N n-ethyl-5-fluoro-2-nitroaniline Chemical compound CCNC1=CC(F)=CC=C1[N+]([O-])=O BBXLSURFRDKKLF-UHFFFAOYSA-N 0.000 description 1
- 125000001038 naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 231100001160 nonlethal Toxicity 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 125000006505 p-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C#N)C([H])([H])* 0.000 description 1
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 125000003884 phenylalkyl group Chemical group 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005934 tert-pentyloxycarbonyl group Chemical group 0.000 description 1
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 1
- IBWGNZVCJVLSHB-UHFFFAOYSA-M tetrabutylphosphanium;chloride Chemical compound [Cl-].CCCC[P+](CCCC)(CCCC)CCCC IBWGNZVCJVLSHB-UHFFFAOYSA-M 0.000 description 1
- YMBCJWGVCUEGHA-UHFFFAOYSA-M tetraethylammonium chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC YMBCJWGVCUEGHA-UHFFFAOYSA-M 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 125000005425 toluyl group Chemical group 0.000 description 1
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23598809P | 2009-08-21 | 2009-08-21 | |
| US61/235,988 | 2009-08-21 | ||
| PCT/JP2010/064040 WO2011021676A1 (ja) | 2009-08-21 | 2010-08-20 | ベンゾ［ｂ］［１，４］ジアゼピン－２，４－ジオン化合物の製造方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2012110566A RU2012110566A (ru) | 2013-09-27 |
| RU2553676C2 true RU2553676C2 (ru) | 2015-06-20 |
Family
ID=43607124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012110566/04A RU2553676C2 (ru) | 2009-08-21 | 2010-08-20 | СПОСОБ ПОЛУЧЕНИЯ ПРОИЗВОДНОГО БЕНЗО[b][1,4]ДИАЗЕПИН-2,4-ДИОНА |
Country Status (11)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL316449A (en) | 2022-04-28 | 2024-12-01 | Daiichi Sankyo Co Ltd | Benzotriazole compound |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU455539A3 (ru) * | 1970-11-02 | 1974-12-30 | К.Х.Берингре Зон (Фирма) | Способ получени 2-алкокси-5 фенил-4н-3,5-дигидро-1,5-бензодиазепин-4-онов |
| US4001408A (en) * | 1966-12-14 | 1977-01-04 | Roussel-Uclaf | Substituted heterocyclic compounds, processes and composition including those |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1005A (en) * | 1838-11-12 | Ing and heating booms and other apabtments beqtjibing abtrficial | ||
| US3133056A (en) | 1961-05-15 | 1964-05-12 | May & Baker Ltd | N-phenylpiperazine derivatives of tetrahydrobenzodiazepines |
| BE707667A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1966-12-14 | 1968-06-07 | ||
| US3984398A (en) * | 1966-12-14 | 1976-10-05 | Roussel-Uclaf | 1,5-Benzodiazepine-2,4-diones |
| GB1460936A (en) | 1974-10-01 | 1977-01-06 | Beecham Group Ltd | Benzodiazepines |
| NZ187452A (en) | 1977-06-10 | 1980-05-27 | Otsuka Pharma Co Ltd | N- substituted-aminocarbonylpropoxy-carbostyrils and their preparation |
| JPS56122356A (en) | 1980-02-29 | 1981-09-25 | Otsuka Pharmaceut Co Ltd | Carbostyril derivative |
| JP2753622B2 (ja) | 1988-05-02 | 1998-05-20 | 大塚製薬株式会社 | カルボスチリル誘導体 |
| JPH0296133A (ja) | 1988-10-01 | 1990-04-06 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
| BR9200951A (pt) | 1991-03-21 | 1992-11-17 | Hoffmann La Roche | Compostos, processo para sua producao,preparacoes farmaceuticas e uso |
| WO1993004042A1 (fr) | 1991-08-23 | 1993-03-04 | Otsuka Pharmaceutical Co., Ltd. | Derive de carbostyrile et antiagregant plaquettaire |
| PE27497A1 (es) | 1994-04-15 | 1997-08-07 | Glaxo Inc | Derivados de 1,5 benzodiazepina |
| US5700797A (en) * | 1995-06-07 | 1997-12-23 | Merck & Co, Inc. | N-(2,4-dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3-yl)-3-amides |
| US5691331A (en) | 1995-06-07 | 1997-11-25 | Merck & Co., Inc. | N-(2,4-Dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3yl) -3- amides |
| TW338037B (en) | 1995-10-05 | 1998-08-11 | Otsuka Pharma Co Ltd | Carbostyril derivatives possessing platelet aggregation inhibitory activity, antithrombotic activity, intima thinkening, inhibitory activity and phosphoriesterase inhibitory activity, their preparation and pharmaceutical composition |
| GB0008179D0 (en) | 2000-04-05 | 2000-05-24 | Glaxo Group Ltd | Chemical process |
| AU6895000A (en) | 1999-08-09 | 2001-03-05 | Merck & Co., Inc. | Antiarrhythmic compounds |
| US6949542B2 (en) | 2002-02-06 | 2005-09-27 | Hoffman-La Roche Inc. | Dihydro-benzo[b][1,4]diazepin-2-one derivatives |
| US7772433B2 (en) | 2002-02-28 | 2010-08-10 | University Of Tennessee Research Foundation | SARMS and method of use thereof |
| BR0317591A (pt) | 2002-12-20 | 2005-11-22 | Amgen Inc | Composto, sal ou pró-medicamento farmaceuticamente aceitáveis, composição farmacêutica, e, métodos para tratar uma doença ou condição, para modular a função de crth2 e/ou um ou mais outros receptores de pgd2 em uma célula e para modular crth2 e/ou um ou mais outros receptores de pgd2 |
| TWI329641B (en) | 2005-08-31 | 2010-09-01 | Otsuka Pharma Co Ltd | (benzo[b]thiophen-4-yl)piperazine compounds, pharmaceutical compositions comprising the same, uses of the same and processes for preparing the same |
| PL2254873T3 (pl) * | 2008-02-22 | 2014-10-31 | Otsuka Pharma Co Ltd | Związek benzodiazepinowy i kompozycja farmaceutyczna |
| TWI481601B (zh) * | 2009-08-21 | 2015-04-21 | Otsuka Pharma Co Ltd | 含氮化合物及藥學組成物 |
-
2010
- 2010-08-20 IN IN986DEN2012 patent/IN2012DN00986A/en unknown
- 2010-08-20 CN CN201080037096.9A patent/CN102639512B/zh not_active Expired - Fee Related
- 2010-08-20 EP EP10810017A patent/EP2468733A4/en not_active Withdrawn
- 2010-08-20 US US13/391,468 patent/US8796447B2/en not_active Expired - Fee Related
- 2010-08-20 RU RU2012110566/04A patent/RU2553676C2/ru not_active IP Right Cessation
- 2010-08-20 CA CA2771136A patent/CA2771136A1/en not_active Abandoned
- 2010-08-20 KR KR1020127007170A patent/KR20120065360A/ko not_active Ceased
- 2010-08-20 BR BR112012003871A patent/BR112012003871A2/pt not_active IP Right Cessation
- 2010-08-20 WO PCT/JP2010/064040 patent/WO2011021676A1/ja active Application Filing
- 2010-08-20 JP JP2011527709A patent/JP5649577B2/ja not_active Expired - Fee Related
-
2012
- 2012-01-31 IL IL217855A patent/IL217855A/en not_active IP Right Cessation
-
2014
- 2014-03-10 US US14/202,793 patent/US8940889B2/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4001408A (en) * | 1966-12-14 | 1977-01-04 | Roussel-Uclaf | Substituted heterocyclic compounds, processes and composition including those |
| SU455539A3 (ru) * | 1970-11-02 | 1974-12-30 | К.Х.Берингре Зон (Фирма) | Способ получени 2-алкокси-5 фенил-4н-3,5-дигидро-1,5-бензодиазепин-4-онов |
Also Published As
| Publication number | Publication date |
|---|---|
| JP5649577B2 (ja) | 2015-01-07 |
| EP2468733A4 (en) | 2013-02-06 |
| WO2011021676A1 (ja) | 2011-02-24 |
| US8940889B2 (en) | 2015-01-27 |
| CA2771136A1 (en) | 2011-02-24 |
| EP2468733A1 (en) | 2012-06-27 |
| US20120149899A1 (en) | 2012-06-14 |
| CN102639512B (zh) | 2015-12-09 |
| RU2012110566A (ru) | 2013-09-27 |
| BR112012003871A2 (pt) | 2015-09-08 |
| IL217855A (en) | 2016-08-31 |
| JPWO2011021676A1 (ja) | 2013-01-24 |
| US8796447B2 (en) | 2014-08-05 |
| US20140194621A1 (en) | 2014-07-10 |
| IN2012DN00986A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2015-04-10 |
| KR20120065360A (ko) | 2012-06-20 |
| IL217855A0 (en) | 2012-03-29 |
| CN102639512A (zh) | 2012-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101170184B1 (ko) | 벤즈이미다졸 유도체, 그를 포함하는 조성물, 및 그의 제조방법 및 그의 용도 | |
| JP3939246B2 (ja) | インドロキナゾリノン類 | |
| US5691331A (en) | N-(2,4-Dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3yl) -3- amides | |
| JPH04234860A (ja) | チアジン（又はオキサジン）誘導体、その製法及びその合成中間体 | |
| US6235752B1 (en) | Isoquinolinamine and phthalazinamine derivatives which interact with CRF receptors | |
| PT100860A (pt) | Novos derivados de beta-carbolionas, processo para a sua preparacao e composicoes farmaceuticas que as contem | |
| RU2553676C2 (ru) | СПОСОБ ПОЛУЧЕНИЯ ПРОИЗВОДНОГО БЕНЗО[b][1,4]ДИАЗЕПИН-2,4-ДИОНА | |
| JPS61286367A (ja) | ベンズアゼピン誘導体 | |
| AU609169B2 (en) | Benzazepines derivatives | |
| PL117107B1 (en) | Process for preparing novel 4a,9b-trans-5-aryl-2,3,4,4a,5,9b-hexahydro-1h-pyrido/4,3-b/indoles-geksagirdid 1h-pirido 4,3-b ionidolov | |
| JPH0686435B2 (ja) | ベンズアゼピン誘導体 | |
| JP2005501028A (ja) | ベナゼプリル及びその類似体の生産に有用な中間体の速度論的分離 | |
| US6432974B1 (en) | Pyrrolo-isoquinoline and tetra-hydropyrrolo-isoquinoline derivatives and their use as mediators of the 5-HT7 receptor | |
| CN113651767B (zh) | 一种苯并异噁唑类杂环化合物及其制备方法和应用 | |
| US4578397A (en) | Indeno(1,2-b)pyrrole derivatives | |
| Tsunoda et al. | A new synthetic route to YM087, an arginine vasopressin antagonist | |
| DK156391B (da) | Analogifremgangsmaade til fremstilling af 3-aminopyrrolderivater | |
| CN113214142B (zh) | 一种阿哌沙班的中间体及制备方法 | |
| JPS6157582A (ja) | 新規なベンゾジアゼピン類 | |
| US6214823B1 (en) | Benzodiazepine derivatives as antiarrhythmic agents | |
| JP2781277B2 (ja) | ベンズアゼピン誘導体及びその医薬組成物並びに中間体 | |
| EP2093218A1 (en) | Arylalkyl substituted imidazolidinones | |
| JPS6250463B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| JPS6247186B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| JPH0556345B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20160821 |